We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Unraveling the Molecular Interactions That Enable Nutlin-Class Drugs to Kill Cancer Cells

By LabMedica International staff writers
Posted on 01 Mar 2016
Print article
Image: Binding of a Nutlin to the enzyme mdm2 (shown in red) (Photo courtesy of the BioChemoInformatics Lab, Bologna, Italy).
Image: Binding of a Nutlin to the enzyme mdm2 (shown in red) (Photo courtesy of the BioChemoInformatics Lab, Bologna, Italy).
Loss of the PUMA (p53 upregulated modulator of apoptosis) gene has been shown to protect tumor cells from being killed by the Nutlin class of experimental anticancer drugs.

Nutlins are cis-imidazoline analogs that inhibit the interaction between the enzyme mdm2 (mouse double minute 2 homolog) and the tumor suppressor protein p53. MDM2 is an E3 ubiquitin-protein ligase that binds to p53 and targets it to ubiquitin-mediated degradation in proteasomes. Inhibiting the interaction between mdm2 and p53 stabilizes p53 and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or "wild-type" p53. Nutlin3a, which is the forerunner of a class of cancer therapeutics that have reached clinical trials, has been shown to affect the production of p53 within minutes.

Investigators at the Walter and Eliza Hall Institute (Melbourne, Australia) used transgenic and gene-targeted mouse models lacking the critical p53 target genes, p21, Puma, and Noxa (phorbol-12-myristate-13-acetate-induced protein 1) to study the interactions involving Nutlin3a, mdm2, and PUMA.

The investigators reported in the February 18, 2016, online edition of the journal Cell Reports that only loss of PUMA conferred profound protection against Nutlin3a-induced killing in both non-transformed lymphoid cells and in lymphoma cells in vitro and in vivo. In addition, CRISPR/Cas9-mediated targeting of the PUMA gene rendered human hematopoietic cancer cell lines markedly resistant to Nutlin3a-induced cell death.

These results demonstrated that PUMA-mediated apoptosis, but not p21-mediated cell-cycle arrest or senescence, was a critical determinant of the therapeutic response to p53 activation by Nutlin3a. Importantly, in human cancer, PUMA expression may predict patient responses to treatment with drugs that target mdm2.

"When functioning properly, p53 is activated in response to early cancerous changes in the cell," said senior author Dr. Andreas Strasser, a professor in the molecular genetics of cancer division at the Walter and Eliza Hall Institute. "P53 acts by either halting the cell while repairs are made or by forcing the cell to die if it cannot be repaired. Without the "help" of P53, a damaged cell can be allowed to multiply, leading to cancer development. P53 lies dormant in many types of cancer that do not have mutations in P53, and the nutlins work through re-awakening its activity. By understanding how nutlins are killing cancer cells, we can begin to formulate their best possible use, including choosing the best partner drugs to combine the nutlins with."

Related Links:

Walter and Eliza Hall Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.